This page explains South Africa’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.
Can a 2024 safety statement settle a product's current approval status?
No. Later approved product information can change the position; use the current medicine-specific document.
Later approvals change the picture
SAHPRA's repository contains Wegovy professional information with a February 2025 first authorisation date. Mounjaro professional information dated December 2025 includes weight management. Older statements describing the earlier diabetes-only position should not replace those documents.
Registration is not funding
These regulatory documents do not establish routine public funding or a medical scheme's benefit. Ask your clinician and scheme to confirm coverage for the exact indication and product, including any authorisation requirements and your own payment.
Evaluate the supplied product
SAHPRA and the Pharmacy Council reported enforcement against unlawful commercial manufacture of unregistered GLP-1/GIP medicines in May 2026. A product described as compounded should not simply be treated as an interchangeable registered brand.
Check the date in UK reporting too
The difference between an older warning and later approval is a useful lesson for UK readers. Check current MHRA information before applying an overseas headline to UK care. South African authorisation and ZAR prices do not establish UK access or cost.
Keep these four questions separate
Access
Current South African product information required
Funding
Public-service and medical-scheme coverage require checking
Cost context
ZAR product charges are not UK care-package prices
Regulatory source
SAHPRA
Sources & further reading
Sources checked . These links support the information above; they do not imply endorsement of this website.
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →
Compare prices